Clinical trials: Conjunctivitis
Allergic Conjunctivitis
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
- Trial name
- NCT01119287
- Testing
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Alcon Research
Conjunctivitis
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.
- Trial name
- NCT00705159
- Testing
- loteprednol etabonate and tobramycin, loteprednol etabonate, Tobramycin
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Bausch & Lomb Incorporated
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000.
- Trial name
- NCT05263505
- Testing
- Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Allergic Conjunctivitis
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
- Trial name
- NCT03494504
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 318 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Hypersensitivity
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever.
- Trial name
- NCT01569191
- Testing
- Artificial Tear Supplement, Cold compress, Anti-allergic Medication
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aston University
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S
Bacterial Conjunctivitis
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
- Trial name
- NCT00518089
- Testing
- Gatifloxacin 0.5% eye drops
- Where
- 2 sites in United States, India
- Volunteers
- 859 people
- Sponsor
- Allergan
Conjunctivitis, Conjunctivitis, Bacterial
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V.
- Trial name
- PRO-174/I (NCT03519516)
- Testing
- PRO-174, Sophixín Ofteno®
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.